Evidence map›Paper›PMID 33647501›Full record

ArticleAnnals of hepatology

Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study.

Paulina Vidal-Cevallos, Fatima Higuera-De-La-Tijera, Norberto C Chávez-Tapia, Francisco Sanchez-Giron, Eira Cerda-Reyes, Victor Hugo Rosales-Salyano, Alfredo Servin-Caamaño, Martín Uriel Vázquez-Medina, Nahum Méndez-Sánchez

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Is single point HbA1c a reliable predictor for death in severe COVID-19?Journal of preventive medicine and hygiene · 2023
    Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Paulina Vidal-CevallosLiver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine. National Autonomous University of Mexico, Mexico City, Mexico; National Autonomous University of Mexico. Mexico City, Mexico, 14050, Mexico.
Fatima Higuera-De-La-TijeraGastroenterology and Hepatology Department, Mexico's General Hospital "Dr. Eduardo Liceaga". Dr. Balmis 148, col. Doctores, C.P. 06720, Mexico City, Mexico.
Norberto C Chávez-TapiaObesity and Digestive Disease Unit, Medica Sur Clinic and Foundation. Puente de Piedra 150, col. Toriello Guerra, C.P. 14050, Mexico City, Mexico.
Francisco Sanchez-GironDirector of the Clinical Pathology Laboratory, Medica Sur Clinic and Foundation. Puente de Piedra 150, col. Toriello Guerra, C.P. 14050, Mexico City, Mexico.
Eira Cerda-ReyesAcademic Coordinator, Central Military Hospital, Periférico Blvrd Manuel Ávila Camacho s/n, col. Militar, C.P. 11200, Mexico City, Mexico.
Victor Hugo Rosales-SalyanoInternal Medicine Department, Mexico's General Hospital "Dr. Eduardo Liceaga". Dr. Balmis 148, col. Doctores, C.P. 06720, Mexico City, Mexico.
Alfredo Servin-CaamañoInternal Medicine Department, Mexico's General Hospital "Dr. Eduardo Liceaga". Dr. Balmis 148, col. Doctores, C.P. 06720, Mexico City, Mexico.
Martín Uriel Vázquez-MedinaSuperior School of Medicine, National Polytechnic Institute Salvador Díaz Mirón S/N, Miguel Hidalgo, Casco de Santo Tomas, C.P. 11340, Mexico City, Mexico.
Nahum Méndez-SánchezLiver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine. National Autonomous University of Mexico, Mexico City, Mexico; National Autonomous University of Mexico. Mexico City, Mexico, 14050, Mexico. Electronic address: nmendez@medicasur.org.mx.
Hospital Médica Sur · MXHospital General de México · MXHospital Central Militar · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesAs of January 2021, over 88 million people have been infected with COVID-19. Almost two million people have died of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high SOFA score and a D-Dimer >1 µg/mL identifies patients with high risk of mortality. High lactate dehydrogenase (LDH) levels on admission are associated with severity and mortality. Different degrees of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) abnormalities have been reported in these patients, its association with a mortality risk remains controversial. The aim of this study was to explore the correlation between LDH and in-hospital mortality in Mexican patients admitted with COVID-19. MATERIALS &

methodsWe performed a retrospective multi-centre cohort study with 377 hospitalized patients with confirmed SARS-CoV-2 in three centres in Mexico City, Mexico, who were ≥18 years old and died or were discharged between April 1 and May 31, 2020.

resultsA total of 377 patients were evaluated, 298 (79.1%) patients were discharged, and 79 (20.9%) patients died during hospitalization. Non-survivors were older, with a median age of 46.7 ± 25.7 years old, most patients were male. An ALT > 61 U/l (OR 3.45, 95% CI 1.27-9.37; p = 0.015), C-reactive protein (CRP) > 231 mg/l (OR 4.71, 95% CI 2.35-9.46; p = 0.000), LDH > 561 U/l (OR 3.03, 95% CI 1.40-6.55; p = 0.005) were associated with higher odds for in-hospital death.

conclusionsOur results indicate that higher levels of LDH, CRP, and ALT are associated with higher in-hospital mortality risk in Mexican patients admitted with COVID-19.

Indexed as

Clinical Enzyme TestsHospitalizationHospital MortalityAdultAgedAlanine TransaminaseBiomarkersCOVID-19C-Reactive ProteinFemaleHumansL-Lactate DehydrogenaseMaleMexicoMiddle AgedPredictive Value of TestsAlanine TransaminaseBiomarkersC-Reactive ProteinL-Lactate DehydrogenaseBiochemical markersMortality determinantsPandemics.Retrospective studiesSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID33647501
PMCPMC7908830
OpenAlexW3134566363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.